05/17/22 2:00 AMNasdaq : EVAX managementlow floatInversago Pharma Appoints Glenn S. Vraniak as Chief Financial OfficerInversago Pharma Inc., a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, today announces the appointment of Glenn S. Vraniak to the position of Chief Financial Officer, effective immediately. Before joining Inversago, Mr. Vraniak served as Chief Financial Officer of Evaxion Biotech A/S, an AI enabled immuno-oncology company...RHEA-AIvery positive
05/11/22 7:30 AMNasdaq : EVAX earningslow floatEvaxion Biotech Announces First Quarter 2022 Financial Results and Provides Business UpdateReceived regulatory clearance in Australia to initiate phase 2b trial of lead cancer therapy EVX-01 targeting melanoma Completed recruitment for Phase 1/2a clinical trial for EVX-02 with all patients receiving first dose Announced publication on personalized therapy with EVX-01 in patients withRHEA-AIpositive
05/10/22 7:30 AMNasdaq : EVAX clinical triallow float Evaxion Biotech Announces Successful Production of Personalized Cancer Immunotherapies in Phase 1/2a Clinical Trial for EVX-02Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today that it hasRHEA-AIneutral
04/29/22 12:15 PMNasdaq : EVAX conferenceslow floatEvaxion Biotech to Host Q1 2022 Corporate Update Conference Call & Webcast on May 11Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, announced today that it will present its first-quarter 2022 financialRHEA-AIneutral
04/26/22 8:45 AMNasdaq : PSNL, EVAX Evaxion to Utilize Personalis’ ImmunoID NeXT Platform® to Evaluate Efficacy of Combination Therapy for Late-Stage MelanomaEvaxion Biotech A/S and Personalis announced today that Evaxion will deploy Personalis’ ImmunoID NeXT Platform in a Phase 2 b trial to evaluate the efficacy and safety of Evaxion’ s personalized cancer immunotherapy EVX-01. That means a higher precision in the therapy than the standard of care treatments out there,” said...RHEA-AIneutral
04/06/22 7:30 AMNasdaq : EVAX low floatEvaxion Biotech Hosting Key Opinion Leader Webinar on Metastatic Melanoma and Personalized Cancer ImmunotherapiesEvaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, announced today that it will host a keyRHEA-AIneutral
03/22/22 6:30 AMNasdaq : EVAX earningslow floatEvaxion Biotech Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business UpdateCompleted follow-on public offering (FPO) of 3,942,856 ordinary shares represented by American Depositary Shares (ADSs) raising net proceeds of $24.9 million after deducting underwriting discounts, commissions and other offering expenses Announced clinical trial collaboration and supply agreementRHEA-AIpositive
03/14/22 7:00 AMNasdaq : EVAX low floatEvaxion Biotech Strengthens Management Team with Two Senior AppointmentsEvaxion Biotech A/S (NASDAQ: EVAX) is a clinical-stage biotechnological company specializing in the development of AI-powered immunotherapies to improve the lives of patients with cancer and infectious diseases. Evaxion Biotech announcedRHEA-AIvery positive
03/07/22 7:30 AMNasdaq : EVAX clinical triallow floatEvaxion Biotech Completes Recruitment for Phase 1/2a Clinical Trial for EVX-02Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, has now finalized recruitment for Phase 1/2a clinical trial of EVX-02 in adjuvant melanoma patients. TheRHEA-AIneutral
01/26/22 7:30 AMNasdaq : EVAX clinical triallow floatEvaxion Biotech Announces Publication of Clinical Data of EVX-01 Heading into Phase 2b in Collaboration with MerckEvaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today the publication of aRHEA-AIneutral